Tagged with B

Poland Łukasz Korybalski, regional manager of Becton Dickinson (BD) Central Eastern Europe, discusses the rising significance of the region as the company continues to grow and the strategic importance of Poland, being home to BD’s CEE regional commercial operations and a global shared service centre. Additionally, he highlights the steps they…

Baltics Piret Hirv, Health Technology Division manager at Tallinn Science Park Tehnopol, discusses the match-making role that the Estonian Connected Health Cluster provides between companies and investors and sees as a priority a less Tallinn-centered approach as a way to attract an even more diverse range of organizations. Can you give…

Canada Moving into the position of National Pharma & Life Sciences Leader, PwC’s Rami El-Cheikh announces the firm’s plan to introduce the comprehensive Pharma Advisory Services currently existing in the US into Canada, including enterprise and function-specific service expertise. He further identifies areas of potential growth in healthcare-related industries, putting forward…

Lithuania With over 120,000 people whose lives are affected by the disease in Lithuania; diabetes stands as one of the country’s major health issues today. Furthermore, as Marijus Valatka, general manager for Lithuania, Latvia and Estonia of Novo Nordisk – the world leader in insulin and diabetes drugs – explains, “Lithuania…

Estonia Kristin Raudsepp, director general of Estonia’s drug regulator – the State Agency of Medicines – discusses her organization’s mandate, current priorities, and reactiveness to the pervading trends in international regulation. Can you introduce the State Agency of Medicines of Estonia and its mandate to our international readers? “Despite of the…

Estonia Kadri Maegi-Lehtsi, general manager of Roche Pharmaceuticals Estonia, discusses the company’s established footprint in the Estonian market and their mission to give back to the Estonian society not only by providing innovative and highly needed medicines, but also through awareness and lifestyle campaigns. In Estonia, Roche focuses on marketing and…

Baltics Juris Hmelnickis PhD, Chairman of the Board of JSC Kalceks, explains the story and the evolution of the company in Latvia, its key products in the CNS therapeutic area and how they were able to piggyback on the established footprint of their mother company, JSC Grindeks, to launch products in…

Baltics Rauls Velins, Roche’s general manager for Latvia, introduces the company’s longstanding commitment to the Latvian market, Roche’s role in helping facilitate Latvia’s new National Cancer Plan, and the potential for personalized medicine across the Baltics. Could you please start by introducing Roche in Latvia and the strategic significance of the…

Poland Philippe Coudiere, general manager of Pierre Fabre Dermo-cosmetics Poland, highlights the key partnerships the company has nurtured with pharmacists and dermatologists and the importance of clinical data for their products. Furthermore, he explains the need to develop a strong connection with end consumers and the dynamics of the Polish dermo-cosmetic…

Baltics Kuuno Vaher, market access director Baltics and country lead of AstraZeneca Estonia, discusses the liberal attitude towards innovative and highly needed medicines of Estonian regulators and the crucial importance of closer collaboration with payers, which has led the thriving affiliate to have its portfolio reimbursed in the country. Can you…

Poland Artur Chabowski, president of Mabion, a pioneer Polish biotech player, discusses the historic partnership of their product, MabionCD20 with Mylan for the EU and Baltic states and the opportunities this opens up. Furthermore, he highlights the future potential of the biosimilar market and the company´s plans to design their own…

UK Sarah Haywood, CEO of MedCity, the life science cluster for London, Oxford and Cambridge in the southeast of England, discusses the organization’s strategy, key achievements, Brexit, and supporting SMEs. Why was there a need to create yet another life sciences cluster four years ago? Aren’t there already enough in this…